Benzo [a] pyrene immunogenetics and immune archetype reprogramming of lung
EE Abd El-Fattah, AM Abdelhamid - Toxicology, 2021 - Elsevier
Overexposure to carcinogenic precursor, benzo [a] pyrene [BaP], modulates the lung
immune microenvironment. The present review seeks to elucidate novel pathways behind …
immune microenvironment. The present review seeks to elucidate novel pathways behind …
Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and …
TM Al-Noshokaty, NM Mesbah, DM Abo-Elmatty… - Life Sciences, 2022 - Elsevier
Aims The first-line treatment for advanced hepatocellular carcinoma (HCC) is the
multikinase inhibitor sorafenib (SOR). Sofafenib resistance is linked to protein kinase …
multikinase inhibitor sorafenib (SOR). Sofafenib resistance is linked to protein kinase …
Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach
EE Abd El-Fattah, AY Zakaria - International Immunopharmacology, 2022 - Elsevier
Hyperinsulinemia, hyperglycemia, and chronic inflammation may play a role in
hepatocellular carcinoma (HCC). Treatment of HCC patients with the antidiabetic medication …
hepatocellular carcinoma (HCC). Treatment of HCC patients with the antidiabetic medication …
Combining crocin and sorafenib improves their tumor-inhibiting effects in a rat model of diethylnitrosamine-induced cirrhotic-hepatocellular carcinoma
Simple Summary Liver cancer represents one of the most lethal forms of cancer, with
hepatocellular carcinoma (HCC) accounting for the majority of its incidences and deaths …
hepatocellular carcinoma (HCC) accounting for the majority of its incidences and deaths …
[HTML][HTML] Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling
S Saber, EE Abd El-Fattah, AM Abdelhamid… - Biomedicine & …, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is the third foremost cause of cancer-related deaths. HCC
has a very bad prognosis because it is asymptomatic in the early stages, resulting in a late …
has a very bad prognosis because it is asymptomatic in the early stages, resulting in a late …
Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway
In hepatocellular carcinoma (HCC), sorafenib (Sora) efficacy is limited by primary and/or
acquired resistance. Emerging evidence shows that the inflammatory factor interleukin 6 (IL …
acquired resistance. Emerging evidence shows that the inflammatory factor interleukin 6 (IL …
AKT-AMPKα-mTOR-dependent HIF-1α activation is a new therapeutic target for cancer treatment: a novel approach to repositioning the antidiabetic drug sitagliptin for …
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
[HTML][HTML] Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
AM Abdelhamid, S Saber, ME Youssef… - Biomedicine & …, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is on the rise worldwide, and its incidence in diabetic
patients is two to three times that of non-diabetics. Current therapeutic options fail to provide …
patients is two to three times that of non-diabetics. Current therapeutic options fail to provide …
Targeting CD166+ lung cancer stem cells: Molecular study using murine dendritic cell vaccine
NE El-Ashmawy, ML Salem, EE Abd El-Fattah… - Toxicology and applied …, 2021 - Elsevier
Purpose Cancer stem cells (CSC) are the most common causes of lung cancer relapse and
mouse resistance to chemotherapy. CD166 was identified as CSC marker for lung cancer …
mouse resistance to chemotherapy. CD166 was identified as CSC marker for lung cancer …
Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7
Abstract Aims Sorafenib (Sora) represents one of the few effective drugs for the treatment of
advanced hepatocellular carcinoma (HCC), while resistance and cardiotoxicity limit its …
advanced hepatocellular carcinoma (HCC), while resistance and cardiotoxicity limit its …